The recent study of Speel and co-workers 1 was designed to test whether or not a high dose of sildenafil could replace a single low dose intracorporeal injection (ICI) during pharmaco-penile duplex ultrasonography (PPDU). Eleven erectile dysfunction (ED) patients entered this cross-over study, and underwent PPDU twice with an interval of 2 weeks; six patients started with sildenafil plus visual erotic stimulation (VES), five started with ICI without VES.
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Although the authors consider their article a 'preliminary report' they are less hesitant in the conclusions they reach on the basis of this study: 'sildenafil may replace ICI as mode of stimulation during PPDU'. On the basis of their experimental design they should not reach such a conclusion. It is quite significant that in the sildenafil mode the patients start the duplex scanning simultaneously with VES, whereas there is no VES in the ICI mode. This is surprising in light of earlier publications of the same group of investigators where they found that VES stimulation in ED patients together with a low dose ICI during PPDU (also recommended by Montorsi et al 2 ) yielded significantly higher erectile response rates than ICI or VES alone. 3 Even a simple self-report instrument as the post-investigation questionnaire reduced very significantly (by more than 50%) the number of patients with a falsepositive diagnosis of veno-occlusive dysfunction with PPDU. 4 It is further remarkable that the authors do not report on a possible effect of testing order. This could have a significant contribution in a cross-over design, as we have shown earlier, albeit in women, in measuring sexual arousal in the psychophysiological laboratory. 5 In the process of differential diagnosis of ED patients we have advocated the use of visual erotic and vibrotactile stimulation and intracavernous injection in screening men with ED. 6, 7 In a recent retrospective study we compared the PPDU diagnosis and the diagnosis reached through psychophysiological screening (ie VES, vibration and ICI). 8 A total of 44 ED patients had undergone both diagnostic procedures. We concluded that PPDU as a routine screening test in ED patients is of limited value, since 'vascular abnormalities' were found= presumed in more than 50% of patients with psychogenic ED.
We fully agree with the authors when they end their article with the remark that using sildenafil has a disadvantage (over ICI) because the 'patient has to be dosed 1 h before PPDU'. If PPDU is thought to be necessary, we recommend that they simply add VES to their PPDU procedures (as they did in the past 3 ): it is quite effective in reducing false-positive diagnosis of veno-occlusive dysfunction and it is absolutely not more laborious and time-consuming than the use of sildenafil!
